ONCOLOGIC
PROTOCOL
NAVELBINE
- STAGE IV
|
| MAJOR
INDICATIONS: TREATMENTS FOR STAGE IV BREAST
CANCER |
| IDENTIFICATION:
Vinorelbine (Navelbine) |
| This
drug has not been approved by the FDA (Food and
Drug Administration) for the treatment of breast
cancer, but there is evidence from clinical
trials that it is effective against breast
cancer. |
| Doses: 30
mg./M2 |
| Route:
Given intravenously (IV) |
| Duration and timing:
Given once a week |
| Treatments are
generally continued as long as the drug keeps the
breast cancer from growing unless there are
unacceptable side effects. |
Possible Side
effects:
- Hematopoetic:
decrease in blood cells, especially white
cells (neutropenia) but also red cells
(anemia) and or platelets
(thrombocytopenia)
- Gastrointestinal:
possible nausea and vomiting (which may
be decreased or prevented with
medications); constipation; mouth sores;
decreased appetite; abnormalities in
liver function tests
- Integmentary:
hair thinning; if the drug leaks outside
the vein it may damage the skin and cause
scarring
- Fertility:
effect on fertility is unknown; this drug
should not be taken by women who are
pregnant or breast feeding
- Cardiovascular:
irritation to the vein where the drug is
given (phlebitis); chest pain is a rare
side effect and occurs most often in
patients with a history of cardiovascular
disease
- Respiratory:
shortness of breath and/or cough are rare
side effects
- Neurological:
numbness, tingling and/or burning
sensations in hands and/or feet
(peripheral neuropathy); jaw pain; tumor
pain; weakness in the hands or feet
- Other:
fatigue; muscle aches (myalgia)
|
